Janus kinase inhibitors in dermatology: Part I. A comprehensive review

J Am Acad Dermatol. 2022 Feb;86(2):406-413. doi: 10.1016/j.jaad.2021.07.002. Epub 2021 Jul 8.

Abstract

The Janus kinase-signal transducer and activator of transcription (JAK-STAT) intracellular signaling pathway is utilized by many proinflammatory molecules to mediate downstream effects and activate gene transcription. Activation of the JAK-STAT pathway contributes to a number of inflammatory dermatoses. Clinical trials and smaller studies have demonstrated the efficacy of JAK inhibitors in the treatment of a variety of dermatologic conditions. Here, we review the use of JAK inhibitors for the treatment of a wide range of dermatologic diseases in a two-part review series.

Keywords: JAK inhibitor; JAK-STAT pathway; Janus kinase inhibitor; Janus kinase-signal transducer and activator of transcription pathway; dermatology; immunodermatology; immunology; review.

Publication types

  • Review

MeSH terms

  • Dermatology*
  • Humans
  • Janus Kinase 1
  • Janus Kinase Inhibitors* / pharmacology
  • Janus Kinase Inhibitors* / therapeutic use
  • Janus Kinases
  • STAT Transcription Factors
  • Signal Transduction

Substances

  • Janus Kinase Inhibitors
  • STAT Transcription Factors
  • Janus Kinase 1
  • Janus Kinases